VJHemOnc is committed to improving our service to you

ASCO 2019 | CD19 and CD20 CAR T-cell therapy for non-Hodgkin lymphoma

VJHemOnc is committed to improving our service to you

Nirav Niranjan Shah

Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, Milwaukee, WI, discusses the first bispecific chimeric antigen receptor (CAR) T-cell trial for patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Dr Shah tells us about the high response rates and complete remissions witnessed in patients treated in the Phase I trial (NCT03019055), which studied differing dose levels of CAR T-cell products that target both CD-19 and CD-20. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter